Form 4: Recursion Pharmaceuticals Director Borgeson Sells Shares Under 10b5-1 Plan

Director Blake Borgeson of Recursion Pharmaceuticals sold 20,054 shares of Class A Common Stock on March 19, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 19, 2024, Blake Borgeson, a director at Recursion Pharmaceuticals, sold 20,054 shares of Class A Common Stock.
• The sale was executed under a 10b5-1 trading plan adopted on August 18, 2023.
• The shares were sold at a weighted average price of $10.792.
• The price range for individual sales varied from $10.55 to $11.14 per share.
• Following the transaction, Borgeson still beneficially owns 7,252,755 shares of Recursion Pharmaceuticals.
• The sale was reported on a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the sale was conducted under a pre-arranged 10b5-1 trading plan, indicating it was likely planned and not necessarily based on current company performance or future expectations.

Industry Context

Sales by insiders are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares over a period of time while avoiding concerns about insider trading. The market typically views these sales in the context of the overall health and prospects of the company.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates